Fleebs-Logo
Details werden geladen...

EQS-Adhoc: Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027 | 19.10.26 | finanzen.at

EQS-Ad-hoc: Pentixapharm Holding AG / Key word(s): Forecast / Full year Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enr...

Ähnliche Seiten

https://www.finanzen.ch/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-2026-earnings-guidance-raised;-first-patient-enrollment-in-panda-phase-3-study-now-expected-in-the-first-quarter-of-2027-1036640851

EQS-Adhoc: Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027 | 19.10.26 | finanzen.ch

https://www.finanzen.ch/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-2026-earnings-guidance-raised;-first-patient-enrollment-in-panda-phase-3-study-now-expected-in-the-first-quarter-of-2027-1036640851
https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-dhl-ag-dhl-ag-raises-full-year-2026-earnings-guidance-1036635025

EQS-Adhoc: DHL AG: DHL AG raises full-year 2026 earnings guidance | 16.10.26 | finanzen.at

https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-dhl-ag-dhl-ag-raises-full-year-2026-earnings-guidance-1036635025
https://www.finanzen.ch/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-ergebnisprognose-2026-angehoben;-aufnahme-des-ersten-patienten-in-panda-phase-3-studie-nunmehr-fuer-das-erste-quartal-2027-erwartet-1036640850

EQS-Adhoc: Pentixapharm Holding AG: Ergebnisprognose 2026 angehoben; Aufnahme des ersten Patienten in PANDA Phase-3-Studie nunmehr für das erste Quartal 2027 erwartet | 19.10.26 | finanzen.ch

https://www.finanzen.ch/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-ergebnisprognose-2026-angehoben;-aufnahme-des-ersten-patienten-in-panda-phase-3-studie-nunmehr-fuer-das-erste-quartal-2027-erwartet-1036640850
https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-ergebnisprognose-2026-angehoben;-aufnahme-des-ersten-patienten-in-panda-phase-3-studie-nunmehr-fuer-das-erste-quartal-2027-erwartet-1036640850

EQS-Adhoc: Pentixapharm Holding AG: Ergebnisprognose 2026 angehoben; Aufnahme des ersten Patienten in PANDA Phase-3-Studie nunmehr für das erste Quartal 2027 erwartet | 19.10.26 | finanzen.at

https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-ergebnisprognose-2026-angehoben;-aufnahme-des-ersten-patienten-in-panda-phase-3-studie-nunmehr-fuer-das-erste-quartal-2027-erwartet-1036640850
https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-sgl-carbon-se-reports-preliminary-sales-and-earnings-figures-for-the-first-nine-months-and-raises-its-forecast-for-2026-1036601457

EQS-Adhoc: SGL Carbon SE reports preliminary sales and earnings figures for the first nine months and raises its forecast for 2026 | 06.10.26 | finanzen.at

https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-sgl-carbon-se-reports-preliminary-sales-and-earnings-figures-for-the-first-nine-months-and-raises-its-forecast-for-2026-1036601457
https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-bafin-concludes-financial-reporting-review-of-the-2024-consolidated-financial-statements-with-an-error-finding-1036594463

EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding | 02.10.26 | finanzen.at

https://www.finanzen.at/nachrichten/aktien/eqs-adhoc-pentixapharm-holding-ag-bafin-concludes-financial-reporting-review-of-the-2024-consolidated-financial-statements-with-an-error-finding-1036594463